Objective To observe and analyze the clinical manifestations and outcomes of chronic myelogenous leukemia(CML)patients treated with tyrosine kinase inhibitor (TKI)after drug discontinuation criteria.Methods The clinical data of 44 eligible CML patients who discontinued TKI from January 1,2015 to December 31,2017 in the Department of Hematology of Guangdong Huazhong University of Science and Technology Union Shenzhen Hospital and were followed up for a long time were retrospectively analyzed,and the situation of treaty-free remission after discontinuation of TKI and its influencing factors were observed.Results The median time of 44 patients receiving TKI was 59.5 (37,102) months.Among them,40 patients had a history of reduction.All patients obtained the efficacy of major molecular remission(MMR)or above before discontinuation.At a median follow-up of 15(5,30)months,34 patients(77.27%)achieved long-term treatment free remission (TFR).Ten patients (22.73%) lost MMR.In 10 patients who lost MMR,drug therapy was restarted,and 8 of them achieved efficacy above MMR after restart.Kaplan-Meier method was used to analyze the clinical characteristics of 44 patients before drug discontinuation,34 patients finally obtained TFR,and 10 patients relapsed after drug discontinuation,with a recurrence rate of 29.41%.Univariate analysis showed that there were no significant differences in gender,age,MMR acquisition time and Sokal score between the two groups (P＞0.05).The difference was statistically significant in the recurrence rate between patients with MMR maintenance time＜24 months before drug discontinuation and patients with MMR maintenance time≥24 months before drug discontinuation (P＜0.05).Multivariate analysis by logistic regression model showed that MMR maintenance time＜24 months (β=0.519,OR=2.951,95%CI=1.187-7.526) was an independent risk factor for molecular relapse in CML patients (P＜0.05).Conclusion TKI can be stopped only after CML patients meet the criteria for drug discontinuation,and the longer MMR maintenance time before drug discontinuation,the lower the recurrence rate of patients after drug discontinuation.
Sasaki K，Strom SS，O'Brien S，et al.Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era：analysis of patient data from six prospective clinical trials[J].Lancet Haematol，2015，2（3）：e186-e193.
[5]
Ross DM，Branford S，Seymour F，et al.Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease：Resultsfrom the TWISTER study[J].Blood，2013，122（4）：515-522.
Bower HM，Dickman W，et al.Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population[J].J Clin Oncol，2016，34（24）：2851-2857.
[11]
Etienne G，Guilhot J，Rea D，et al.Long-term follow-up of the French Stop Imatinib（STIM1）study in patients with chronic myeloid leukemia[J].J Clin Oncol，2017，35（3）：298-305.
[12]
Kimura S，Imagawa J，Murai K，et al.Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia（first-line DADI trial）：a single-arm，multicentre，phase 2 trial[J].Lancet Haematol，2020，7（3）：e218-e225.
[13]
Saussele S，Richter J，Guilhot J，et al.Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia（EURO-SKI）：a prespecified interim analysis of a prospective，multicentre，non-randomised，trial[J].LancetOncol，2018，19（6）：747-757.
[14]
Aleem A，Alotaibi G，Iqbal Z，et al.Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia[J].Int J Hematol，2023，118（2）：288-291.
[15]
Kaehler M，Cascorbi I.Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia[J].Handb Exp Pharmacol，2023，280（21）：65-83.
[16]
Chen B，Dai H，Yang J，et al.Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma[J].Curr Cancer Drug Targets，2023，23（7）：564-571.
京公网安备 11010502046607号